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SUMMARY 
HIV causes immunodeficiency by infection, lyses and depletion of CD4 T-lymphocytes; 
hence CD4 count has become a valuable indicator of immune function in the management of 
HIV infection. Consequently, we evaluated baseline CD4 counts of 500 HIV seropsitive 
adults in a government sponsored anti-retroviral treatment (ART) scheme at our centre, for 
the purpose of monitoring subsequent response to anti-retrovirals.    The overwhelming 
majority (92%) of our patients were within the sexually active, 3rd to 5th decade age group, 
and the mean CD4 count was 302 cells/µl. Half of our patients (251 cases) had AIDS as 
defined by CD4 count <200 cells/µl and 72% had CD4 count <350 cells/µl, the WHO 
recommended criterion for instituting ART. In general our HIV seropositives had CD4 
counts comparable to other studies here in Nigeria and the West African sub-region, but 
higher than in East Africa and Europe. In view of the well documented higher CD4 count of 
West Africans, it might be necessary to upwardly review the WHO recommended 350 
cells/µl benchmark for instituting ART.   
 
[Afr J Health Sci. 2007; 14:212-215] 
 
Introduction 
 Using CD4 and CXCR4 cell surface molecules as 
receptor and co-receptor respectively; HIV infects T-
helper lymphocytes, replicates within them and lyses 
the cells as the replicated virions are released 
extracellularly to infect yet other CD4 cells [1,2]. 
Consequently CD4+ T-helper lymphocytes are 
gradually depleted and the immune system crippled 
[1,2]. Since CD4 lymphocytes are the most crucial 
cells in adaptive immunity that direct and coordinate 
the functions of other adaptive immune cells (B-
lymphocytes, CD8 lymphocytes & monocytes / 
macrophages), the devastating effect of HIV on the 
immune system is not surprising. 
          Given that HIV induced immunodeficiency is 
largely due to infection and gradual depletion of 
CD4+ T-helper cells, CD4 count has become a useful 
indicator of immune function in infected patients. 
Hence CD4 count along with viral load (HIV-RNA) 
is invaluable in management of HIV infection, 
particularly in monitoring response to anti-retroviral 
therapy (ART) [3, 4, 5]. CD4 count is said to be the 
most reliable prognostic indicator of immune 
response to therapy [3, 6, 7], and is thus a major 
criterion in the CDC/WHO classification of HIV  
 
infection, which is widely used to categorize patients 
for clinical management [8]. With the introduction of 
heavily subsidized ART by the Nigerian Federal 
government in several tertiary health institutions 
around the country – including Aminu Kano 
Teaching Hospital here in Kano – it became 
necessary to monitor the CD4 lymphocyte counts of 
HIV patients managed under the subsidized ART 
scheme. This study endeavours to appraise the 
baseline CD4 profile of HIV seropositive patients at 
the commencement of anti-retroviral treatment. 
 
Materials and Methods 
Six hundred adults were recruited for this study – 100 
healthy controls and 500 HIV seropositive patients. 
The HIV seropositives were recruited from patients 
attending the HIV/AIDS clinic at Aminu Kano 
Teaching hospital, Kano over a 15 month period from 
April 2002 to June 2003. Our healthy controls were 
randomly selected seronegative students of a local 
tertiary educational institution and seronegative 
pregnant women attending ante-natal clinc at the 
teaching hospital. 
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       Children were excluded from this study because 
initially the Federal Ministry of Health, subsidized 
ART scheme was only targeted at adults. Laboratory 
diagnosis of HIV infection was established by double 
ELISA technique (Capillus & Immunocomb), and 
CD4 count was estimated manually by Dynal 
Enumeration Technique. The CD4 lymphocytes were 
counted prior to commencement of ART and at six 
month intervals thereafter. Only the baseline data at 
the beginning of therapy was used for this study. 
 
Results   
Of the 500HIV positive patients, 307 were males and 
193 were females (M: F = 1.6:1). Although the age 
range was quite wide (18-64 years), most patients 
(92%) fell within the 3rd to 5th decades. About half 
of the patients (251cases) had AIDS as defined by 
CD4 count below 200 cells/µl [8]. Seventy two 
percent of our study subjects (359 cases) had CD4 
count <350 cells/µl – the WHO laboratory criteria for 
instituting ART in a resource limited setting [9,10] 
such as here in Northern Nigeria. Only 9.6% (48 
cases) had normal CD4 counts i.e. >600 cells/µl. The 
mean CD4 count of HIV seropsitive individuals in 
this study was 302 cells/µl. The healthy controls were 
aged between 18 & 38 years and had CD4 counts 




Figure 1: age distribution of CD4 lymphocyte count among HIV patients in Kano 
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> 60 years Total 
< 100 - 17 47 30 3 - 97 
100 – 199 1 29 64 29 8 2 133 
200 – 299 1 27 42 25 3 1 99 
300 – 399 1 16 26 13 1 - 57 
400 – 499 2 11 12 9 - - 34 
500 – 599 1 6 18 5 2 - 32 
600 – 699 - - 8 - 1 - 9 
700 – 799 1 4 1 - 1 - 7 
800 – 899 - 1 4 - 2 - 7 
900 – 999 - 2 1 1 - - 4 
> 1000 1 4 9 5 1 - 20 
Total 8 117 232 118 22 3 500 
 
Discussion 
Most (92%) of the HIV positive patients in this study 
were within the 3rd to 5th decades age bracket, which 
is not surprising in view of the fact that these are the 
most sexually active age group – heterosexual 
intercourse being the major mode of transmission in 
Africa [11]. However since children in the first two 
decades were largely excluded from this study, the 
age profile is obviously skewed in favour of adults, 
and accentuates the prominence of the sexually active 
age group. In Jos, a neighbouring northern Nigerian 
city, similar study reported this sexually active 3rd to 
5th decade age group comprised 46% (AIDS) and 
59% (HIV positive) [12]. The lower proportion of the 
sexually active age group in their study could be 
partly explained by the inclusion of children.       
Males outnumbered females (M: F = 1.6:1) in this 
series comprising 61.4% of our HIV seropositives. 
This is at variance with the well-documented fact that 
women are biologically and socially more vulnerable 
to HIV infection, particularly in the third world [11]. 
Socio-cultural restrictions on Muslim women here in 
Nigeria’s Islamic north adversely affect hospital 
attendance and may explain the lower proportion of 
women in our study.     
          About half (50%) of our HIV patients had 
AIDS as defined by CD4 count < 200 cells/µl which 
is comparable to 54% in Jos, another northern 
Nigerian city [12].  Obviously the major reason for 
this high proportion of AIDS is because of late 
presentation, largely due to the fact that we are yet to 
imbibe the culture of voluntary screening for early 
detection and treatment. Fear of stigmatization, lack 
of awareness and inadequate trained counseling 
personnel are some of the factors militating against 
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voluntary screening. Many patients only seek medical 
attention and are diagnosed when HIV infection 
becomes complicated by AIDS defining illnesses. 
Blacks in South Africa similarly presented late with 
advanced disease [13]. 
       The mean CD4 count of our HIV patients was 
302 cells/µl, which is higher than 270 cells/µl in the 
UK [14]. A comparative study between HIV patients 
in France and Francophone West Africa similarly 
documented higher CD4 counts in West Africans 
than in Europe [15]. The mean CD4 count for our 
healthy controls – 1295 cells/µl - was also higher 
than the normal mean of 800 to1050 cells/µl in the 
Western world [6,16]. In Switzerland normal CD4 
count was as low as 309 cells/µl [17]. Njoku et al in 
Jos, also reported higher mean CD4 counts in healthy 
controls and HIV patients than in the Western world 
[12]. They attributed this “physiologic 
lymphocytosis” in Africans to common infections in 
our environment. This hypothesis is somewhat 
undermined by reports from East Africa which 
document lower CD4 count than in the Western 
world [18,19]. It thus appears that this “physiologic 
lymphocytosis” is peculiar to West Africans, which 
suggests that genetic factors might also be involved 
rather than just microbial infections from the 
environment.  
             The obvious implication of higher West 
African CD4 count in HIV management is that the 
widely adopted WHO/CDC classification of HIV 
infection based on CD4 count may need to be 
modified for West Africans.  Consequently Anglaret 
et a [15] propose threshold values of 250 and 700 
cells/µl rather than the CDC/WHO recommended 
200 and 500 cells/µl for laboratory categorization of 
HIV infection. Thus it might be necessary to institute 
ART at higher CD4 counts of about 400-500 cells/µl 
in West Africa rather than the present 350 cells/µl. 
With the current benchmark of 350 cells/µl, over 
70% of our patients already qualify for ART. An 
upward review of the benchmark translates to many 
more HIV seropositives requiring ART, which would 
strain the lean financial resources of the subsidized 
ART scheme.  
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